

Supplemental Table S2. Baseline Characteristic before Propensity Score Matching

Characteristic	Teneligliptin (n=3,341)	Sulfonylurea (n=23,781)	Standardized difference, %
Age, yr	62.8±13.7	63.7±14.1	6.7
Women	1,389 (41.6)	9,953 (41.9)	0.6
Index year			
2015	420 (12.6)	5,302 (22.3)	25.8
2016	1,512 (45.3)	11,021 (46.3)	2.2
2017	1,409 (42.2)	7,458 (31.4)	22.6
Glucose-lowering drugs			
Metformin	2,055 (61.5)	15,265 (64.2)	5.6
SU	0	0	0.0
DPP-4i	0	0	0.0
SGLT2i	108 (3.2)	1,148 (4.8)	8.1
TZD	219 (6.6)	1,370 (5.8)	3.3
GLP-1RA	1	61 (0.3)	6.0
Meglitinide	73 (2.2)	449 (1.9)	2.1
AGI	76 (2.3)	1,323 (5.6)	17.0
Insulin	1,217 (36.4)	8,146 (34.3)	4.5
CVD risk treatment			
Low-dose acetylsalicylic acid	909 (27.2)	6,323 (26.6)	1.4
Statin	1,768 (52.9)	9,982 (42.0)	22.0
Antihypertensive therapy	2,090 (62.6)	15,103 (63.5)	2.0
ACE inhibitors	117 (3.5)	991 (4.2)	3.5
ARB	1,525 (45.6)	9,672 (40.7)	10.1
Dihydropyridines	1,009 (30.2)	8,158 (34.3)	8.8
Low-ceiling diuretics	325 (9.7)	2,559 (10.8)	3.4
Beta blockers	847 (25.4)	5,951 (25.0)	0.8
Non-hydropyridines	146 (4.4)	1,076 (4.5)	0.8
High ceiling diuretics	699 (20.9)	4,851 (20.4)	1.3
Aldosterone antagonists	236 (7.1)	1,590 (6.7)	1.5
Warfarin	86 (2.6)	458 (1.9)	4.4
CVD	1,196 (35.8)	8,116 (34.1)	3.5
Myocardial infarction	137 (4.1)	928 (3.9)	1.0
CABG	8 (0.2)	39 (0.2)	1.7
PCI with stent	65 (1.9)	354 (1.5)	3.5
Unstable angina	193 (5.8)	1,185 (5.0)	3.5
Angina pectoris	645 (19.3)	3,934 (16.5)	7.2
Heart failure	447 (13.4)	2,618 (11.0)	7.2
Atrial fibrillation	187 (5.6)	1,119 (4.7)	4.0

*(Continued to the next)***Supplemental Table S2.** Continued

Characteristic	Teneligliptin (n=3,341)	Sulfonylurea (n=23,781)	Standardized difference, %
Stroke	494 (14.8)	3,601 (15.1)	1.0
Hemorrhagic stroke	81 (2.4)	588 (2.5)	0.3
Ischemic stroke	408 (12.2)	3,039 (12.8)	1.7
Peripheral artery disease	41 (1.2)	186 (0.8)	4.5
Chronic kidney disease	255 (7.6)	1,606 (6.8)	3.4
Microvascular disease	1,307 (39.1)	8,347 (35.1)	8.3
Diabetic neuropathy	627 (18.8)	4,057 (17.1)	4.5
Diabetic retinopathy	648 (19.4)	4,027 (16.9)	6.4
Diabetic nephropathy	474 (14.2)	2,494 (10.5)	11.3
Severe hypoglycemia	128 (3.8)	732 (3.1)	4.1
Cancer	669 (20.0)	3,977 (16.7)	8.5
Frailty	452 (13.5)	4,815 (20.2)	18.0

Values are expressed as mean±standard deviation or number (%). SU, sulfonylurea; DPP-4i, dipeptidyl peptidase 4 inhibitor; SGLT2i, sodium-glucose cotransporter-2 inhibitor; TZD, thiazolidinedione; GLP-1RA, glucagon-like peptide-1 receptor agonist; AGI, alpha-glucosidase inhibitors; CVD, cardiovascular disease; ACE, angiotensin converting enzyme; ARB, angiotensin receptor blockers; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention.